Free Trial

Entero Therapeutics (ENTO) Competitors

Entero Therapeutics logo
$0.40 -0.01 (-1.44%)
Closing price 04:00 PM Eastern
Extended Trading
$0.40 +0.00 (+0.25%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENTO vs. PMCB, ORGS, CLDI, ARTL, APLM, CVM, SLXN, OMGA, CELZ, and AIM

Should you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Nuvilex (PMCB), Orgenesis (ORGS), Calidi Biotherapeutics (CLDI), Artelo Biosciences (ARTL), Apollomics (APLM), CEL-SCI (CVM), Silexion Therapeutics (SLXN), Omega Therapeutics (OMGA), Creative Medical Technology (CELZ), and AIM ImmunoTech (AIM). These companies are all part of the "pharmaceutical products" industry.

Entero Therapeutics vs. Its Competitors

Entero Therapeutics (NASDAQ:ENTO) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Entero Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Nuvilex has a beta of -0.42, indicating that its stock price is 142% less volatile than the S&P 500.

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 10.2% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company Overall Sentiment
Entero Therapeutics Neutral
Nuvilex Neutral

Nuvilex's return on equity of 0.51% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -1,063.82% -26.06%
Nuvilex N/A 0.51%0.35%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06MN/AN/A
NuvilexN/AN/A$330K$0.741.49

Summary

Nuvilex beats Entero Therapeutics on 5 of the 6 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTO vs. The Competition

MetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.89M$2.86B$5.45B$8.93B
Dividend YieldN/A2.44%5.22%4.01%
P/E RatioN/A20.4427.2420.06
Price / SalesN/A283.79426.37117.54
Price / CashN/A41.7026.2128.59
Price / Book-0.487.397.925.56
Net Income-$18.06M-$55.04M$3.17B$248.56M
7 Day Performance-0.75%3.43%4.40%7.56%
1 Month Performance-23.65%0.16%2.64%8.54%
1 Year Performance-62.90%4.49%35.04%21.81%

Entero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTO
Entero Therapeutics
N/A$0.40
-1.4%
N/A-62.2%$1.89MN/A0.009
PMCB
Nuvilex
0.8927 of 5 stars
$1.14
+4.6%
N/A-47.3%$7.48MN/A1.544Positive News
High Trading Volume
ORGS
Orgenesis
N/A$1.53
+3.7%
N/AN/A$7.34M$662K0.00150Gap Up
CLDI
Calidi Biotherapeutics
0.3359 of 5 stars
$0.23
flat
N/A-87.6%$7.31M$50K0.0038News Coverage
ARTL
Artelo Biosciences
2.9572 of 5 stars
$9.50
-28.4%
$33.00
+247.4%
+34.8%$7.26MN/A-0.535Gap Up
Trading Halted
High Trading Volume
APLM
Apollomics
0.3344 of 5 stars
$6.38
-2.8%
N/A-66.0%$7.24M$1.49M0.0045Positive News
Gap Down
CVM
CEL-SCI
0.0764 of 5 stars
$2.37
+3.5%
N/A-93.1%$7.19MN/A-4.9443
SLXN
Silexion Therapeutics
N/A$0.80
-1.0%
$5.00
+523.2%
N/A$7.04MN/A0.00N/A
OMGA
Omega Therapeutics
2.2788 of 5 stars
$0.13
-21.8%
$8.50
+6,700.0%
-93.0%$6.92M$8.10M-0.09120Gap Up
CELZ
Creative Medical Technology
N/A$2.64
-0.4%
N/A-29.6%$6.85M$10K-0.695
AIM
AIM ImmunoTech
1.6651 of 5 stars
$8.93
+3.2%
$275.00
+2,981.2%
-76.6%$6.82M$146K-18.9920Gap Up

Related Companies and Tools


This page (NASDAQ:ENTO) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners